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ABSTRACT:
A key determinant of p53-mediated cell fate following various DNA damage 
modalities is p21WAF1/CIP1 expression, with elevated p21 expression triggering cell 
cycle arrest and repressed p21 expression promoting apoptosis. We show that under 
pro-death DNA damage conditions, the DNA-dependent protein kinase (DNA-PKCS) 
is recruited to the p21 promoter where it forms a protein complex with p53. The 
DNA-PKCS-associated p53 displays post-translational modifications that are distinct 
from those under pro-arrest conditions, ablating p21 transcription and inducing cell 
death. Inhibition of DNA-PK activity prevents DNA-PKCS binding to p53 on the p21 
promoter, restores p21 transcription and significantly reduces cell death. These data 
demonstrate that DNA-PKCS negatively regulates p21 expression by directly interacting 
with the p21 transcription machinery via p53, driving the cell towards apoptosis.
INTRODUCTION
The most prevalent reported genetic defect observed 
in human cancer is the loss or inactivation of the tumor 
suppressor protein p53 [1, 2]. In unstressed cells, p53 is 
maintained at a low level by its negative regulator MDM2 
[3, 4] and is at the center of a complex signalling network. 
In response to a broad range of oncogenic stresses including 
DNA damage, chemical exposure or hypoxia, p53 can 
facilitate either DNA repair (promoting cell survival) 
or trigger apoptosis (programmed cell death), thereby 
ensuring the removal of irreparably damaged cells. p53 
is able to dictate these cell fates in large measure because 
it is a transcription factor with sequence-specific DNA-
binding activity that regulates the expression of a plethora 
of genes [5]. Chromatin-immunoprecipitation (ChIP) 
studies revealed that p53 directly binds to approximately 
1600 genes that fall primarily into three categories: 
cell cycle inhibition, apoptosis, and genome stability 
[6]. Despite this wealth of information, the mechanism 
regarding how p53 mediates the choice between life and 
death remains unclear.
The generally accepted dogma for p53-controlled cell 
fate holds that cell cycle arrest is predominantly mediated 
by the expression and activation of the cyclin-dependent 
kinase inhibitor CDKN1A (p21) [7-9], in contrast to 
apoptosis that is primarily controlled by the expression 
and activation of pro-apoptotic genes including Bax [10] 
and PUMA (p53 upregulated modulator of apoptosis) [11, 
12]. While p21’s ability to inhibit both the G1-S and the 
G2-M cell cycle transitions is well established, emerging 
evidence suggests that p21 also possesses potent anti-
apoptotic activity to complement its pro-arrest functions. 
For example, it has been shown that p21 binds to and 
inactivates procaspase 3, thereby inhibiting apoptosis [13]. 
In addition, caspase 2, which acts upstream of caspase 3, is 
transcriptionally repressed by p21 [14]. Furthermore, p21 
can also suppress the induction of pro-apoptotic genes by 
MYC or E2F1 by direct inhibition of their transcription 
functions [15]. There is also evidence that p21 protects 
cells from irradiation-induced apoptosis by blocking 
CDKs involved in the activation of the caspase cascade 
downstream [16] while nutrient starvation induced cell 
death is also suppressed by p21 [17]. Collectively, these 
data suggest that p21 is capable of launching a multi-level 
anti-apoptosis strategy, effectively counteracting the pro-
apoptotic functions of Bax and PUMA. Thus, while the 
induction and presence of pro-apoptotic genes are required Oncotarget 2011; 2:  1094 - 1108 1095 www.impactjournals.com/oncotarget
for the cell to trigger a potent apoptotic response, there is 
also the absolute requirement for the cell to abolish p21 
expression and mediate p21 protein degradation to enable 
apoptosis to proceed.
Since both pro-arrest (p21) and pro-death (e.g. Bax 
and PUMA) elements are downstream transcriptional 
targets of p53, the delicate balance between their expression 
levels necessarily hinges on the selective activation or 
suppression of specific p53 transcriptional activity [18-
22]. In this regard, post-translational modifications of p53 
have been shown to play a central role. Depending on 
the nature of DNA damage or cell stress, p53 undergoes 
different modifications that dictate its ultimate function. 
A  most  common  and  critical  modification  of  p53  is 
ser15 phosphorylation that prevents MDM2-mediated 
monoubiquitination and nuclear export, allowing p53 
to accumulate in the nucleus [4]. The ser46 and ser315 
residues  have  also  attracted  significant  attention  as 
following ser46 phosphorylation, p53 specifically induces 
pro-apoptotic gene expression [23, 24] in contrast to 
ser315 phosphorylation that stimulates the expression 
of p21 [25]. In addition to phosphorylation, acetylation 
of p53 has also been shown to regulate p53-dependent 
transcription (for a review see [26]. The acetylation of 
lys120 was shown as an absolute requirement for PUMA 
and  Bax transcription after p53 promoter recruitment. 
In  contrast,  lysine  382  acetylation  specifically  and 
significantly increased p21 expression [27, 28]. Based on 
these studies, it is clear that there is enormous complexity 
regarding  p53  posttranslational  modifications,  that 
many appear to be stress-specific, and that these diverse 
modifications can activate or repress select target genes 
dictating cell fate.
The phosphatidylinositol 3-kinase-like protein 
kinases (PI3KKs) are large proteins that include Ataxia 
telangiectasia mutated (ATM), ATM and Rad3-related 
(ATR), and the DNA-dependent protein kinase (DNA-
PK) that are each activated following a range of cellular 
stresses and can direct p53 posttranslational modifications. 
The most defined cellular response is the activation of the 
G1 and G2 cell cycle checkpoints mediated by ATM via 
p53 phosphorylation that leads to p21 transcription and 
cell cycle arrest [29, 30]. ATR reinforces this response by 
the phosphorylation of signaling intermediates including 
checkpoint kinase 1 (Chk 1) [31]. The most classically 
defined  DNA-PK  function  is  V(D)J  recombination 
that is responsible for antibody diversity and normal 
immune development (reviewed in [32, 33]). In addition 
to this well characterized role, however, there is now a 
significant  body  of  data  implicating  DNA-PKCS as an 
upstream element of p53, being involved in the latter’s 
posttranslational modification and apoptotic response to 
severe DNA damage [20, 34-37]. It thus appears that ATM/
ATR and DNA-PK play antagonistic roles in dictating 
stress-induced cell fate (cell cycle arrest vs apoptosis) 
through  their  control  of  a  common  element,  p53  [38, 
39]. More recent data suggest that it is the control over 
p53-mediated p21 expression that ultimately determines 
cell fate, with ATM/ATR and DNA-PK promoting and 
suppressing p21 expression, resulting in cell cycle arrest 
and apoptosis, respectively [40-43].
With DNA-PK’s emerging role as an important 
mediator of apoptosis, it is important to understand how 
DNA-PK activation could lead to down-regulation of 
p21. Here we report that under conditions that favor cell 
death, DNA-PKCS forms a protein complex with p53 and 
is recruited to the p21 promoter. This complex formation 
abrogates p21 transcription, preventing cell cycle arrest 
and as a result sets into motion a potent apoptotic response 
to DNA damage. DNA-PKCS does not inhibit the ability 
of p53 to bind to target gene promoters (pro-arrest or 
pro-death), however, only the transcription of the pro-
arrest p21 gene is blocked. DNA-PKCS therefore directly 
interferes with the p53-mediated p21 transcription 
machinery, priming the cell for apoptosis.
RESULTS
p21 expression correlates with cell fate following 
DNA damage
To investigate how p53 can direct cell fate we 
exposed cells to various DNA damaging conditions that 
result in cell cycle arrest, apoptosis, or both. Gemcitabine 
is a chemotherapeutic and an analog of deoxycytidine 
that inhibits DNA synthesis [44]. Doxorubicin is a 
chemotherapeutic anthracycline that creates DNA breaks 
via the inhibition of topoisomerase II [45]. Chromium 
(VI) is a carcinogen that binds DNA, generating adducts, 
single  and  double  strand  DNA  breaks  [46],  while  γ−
irradiation (IR) introduces double strand DNA breaks. 
All four of these DNA damaging agents activated and 
induced significant accumulation of the p53 protein (Fig. 
1A and S1A), however, their effects on cell fate were 
very different. Whereas chromium treatment triggered 
significant apoptosis but no cell cycle arrest (measured 
by caspase-3 cleavage and the accumulation of a sub-G1 
cell population), IR induced almost exclusively cell cycle 
arrest (with little to no apoptosis) (Fig. 1A, 1B and S1B). 
The effects of gemcitabine and doxorubicin fell between 
the two ends of the spectrum, with gemcitabine inducing 
significantly less cell cycle arrest than doxorubicin. These 
four agents therefore provided a full cell fate spectrum 
that allowed us to more precisely characterize the role of 
DNA-PKCS in directing p53-dependent cell fate.
We then investigated the protein expression of key 
p53-regulated genes over time following exposure to each 
agent in a range of classically studied model cancer cell 
lines. As exemplified by the [p53+/+] HCT116 cell line, 
the most dramatic difference between the four treatments Oncotarget 2011; 2:  1094 - 1108 1096 www.impactjournals.com/oncotarget
was noted for p21 expression (Fig. 1C). Whereas IR 
and doxorubicin treatments resulted in the gradual 
accumulation of p21, chromium and gemcitabine caused 
a significant reduction of the protein at 6 and 12 h post 
damage. In contrast to p21, the total protein levels of 
MDM2, PUMA and Bax were equivalently induced by 
each modality investigated. The reduced p21 protein levels 
post gemcitabine or chromium treatment corresponded 
with the lowered transcription of this gene (Fig. 1D and 
S1C) as these agents had no effect on protein stability or 
the half-life of the p21 transcript [20]. Collectively, our 
results are compatible with the view that the reduction in 
p21 expression allows continued cell cycle progression 
which, in the presence of both DNA damage and the 
Figure 1: All DNA damage modalities induce p53 but manifest different p21 expression levels that correlate with cell 
cycle arrest or apoptosis.  (A) [p53+/+] HCT116 cells were exposed to chromium (Cr(VI)), gemcitabine (Gem), doxorubicin (Doxo) or 
γ-irradiation (γ-IR) for the specified times (hr). Cell extracts were subjected to immunoblot analysis for p53, caspase-3 or β-actin expression. 
(B) HCT116 p53+/+ cells were exposed to Cr(VI), Gem, Doxo or γ-IR. At the time points indicated DNA content was analyzed by flow 
cytometry of cells stained with BrdU and propidium iodide. Each plot represents the cell cycle profile at 24 h post damage. Quantification of 
the percentage of the sub-G1, G1 and G2 DNA content was determined for each sample and is represented in each graph (20,000 total events 
counted). (C) HCT116 p53+/+ cell extracts were subjected to immunoblot analysis for p21, MDM2, PUMA, Bax, and β-actin expression. 
(D) Trizol RNA extraction was carried out from [p53+/+] HCT116 cells 12 h post damage; cDNA was generated and the expression level for 
p21 was measured. The mRNA expression levels were normalized to GAPDH mRNA, and are represented as fold increase or decrease over 
untreated cells. Error bars represent the standard deviation obtained from three independent experiments.
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continuous expression of apoptotic proteins, ultimately 
leads to cell death.
Post-translational modifications of p53 bound to 
the p21 promoter
We next questioned whether p53 was recruited to 
the promoters of p21 under each DNA damage modality 
even where expression of this gene was suppressed. 
Accordingly, chromatin immunoprecipitation (ChIP) 
assays were carried out and revealed surprisingly that 
p53 was recruited to both the distal and proximal p21 
promoters irrespective of whether there was active 
p21 gene transcription (Fig. 2 (top panel) and S1D). To 
determine if the p53 bound to the p21 promoters was 
modified differently following each DNA damage regime, 
ChIP analyses were performed using a panel of antibodies 
against specific modified p53 residues. The results (Fig. 
2 and S2) show that while all p21 promoter-bound p53 
was phosphorylated on ser15 following exposure to 
any of the four DNA damage agents, enhanced ser37 
phosphorylation was found primarily on p53 bound 
to the p21 promoters under conditions (chromium or 
gemcitabine) that instigated cell death. Conversely, 
phospho-ser315 and acetyl-lys382 were found mainly on 
p21 promoter-bound p53 under pro-arrest (doxorubicin 
or IR) conditions. These results clearly indicate that 
Figure 2: p21  promoter-bound  p53  is  differently  modified  under  arrest  versus  apoptotic  conditions.    Chromatin 
immunoprecipitation (ChIP) was carried out with [p53+/+] HCT116 cells following mock or 6 h post DNA damage with the indicated 
modalities using the total or isoform-specific anti-p53 antibodies indicated. PCR was performed for either the distal (-2.2 kb) p21 or 
proximal (-1.3 kb) p21 promoter regions. Quantification of the bands following each DNA damage modality was determined in triplicate and 
represented for each promoter region. Error bars in all panels represent the standard deviation obtained from three independent experiments.
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depending on the DNA damage modality, the p53 bound 
to the p21 promoters was modified differently, leading 
to either active p21 transcription (mediating cell cycle 
arrest), or p21 transcription repression (resulting in cell 
death).
While we primarily focused on the p21 promoters, 
we also examined p53 modifications on the MDM2, PUMA 
and Bax promoters under each DNA damage condition 
(Fig. S3). Our results show that p53 phosphorylated at 
ser15 was found on the MDM2 promoter at 6 h post damage 
under all DNA damage conditions, but was bound to the 
PUMA promoter only under conditions that induced cell 
death (chromium or gemcitabine) and only bound to the 
Bax promoter following Cr(VI) exposure. Interestingly, 
p53-ser37 could be detected on both the MDM2  and 
PUMA promoters 6 h post chromium, gemcitabine or 
doxorubicin exposure. No p53-ser37 could be detected on 
the Bax promoter following exposure to any of our DNA 
damage agents. In contrast to other p53 modifications, we 
noted the enhanced recruitment of p53-phopho-ser33 and 
phosphor-ser46 isoforms to all the promoters examined 6 
h post damage with any of our tested agents. Collectively, 
these results indicate that for each p53-dependent cell 
phenotype (pro-arrest or cell death) there are significantly 
different p53 post translational profiles.
Figure 3: DNA-PKCS activation under pro-apoptotic conditions is independent of ATM/ATR and forms a complex 
with p53. (A) [p53+/+] HCT116 cells were pre-incubated with the DNA-PK inhibitor NU-7026 (10 µM) or the ATM/ATR inhibitor CGK-
733 (20 µM) and exposed to Cr(VI), Gem, Doxo or γ-IR for 12 h. Cell extracts were prepared and subjected to immunoblot analysis for 
total DNA-PKCS or P-thr2609 DNA-PKCS. (B) The cell extracts from (A) were subjected to immunoblot analysis for total p53. (C) [p53+/+] 
HCT116 cells were exposed to Cr(VI), Gem, Doxo or γ-IR for the specified times. Cell extracts were prepared, immunoprecipitated (IP) 
with an anti-DNA-PKCS or anti-p53 antibody, and subjected to western blot (WB) analysis for p53 or DNA-PKCS. Immunoblots for total 
p53 and total DNA-PKCS in the extracts are also shown. (D) (left) Extracts prepared from 12 h post damage cells were immunoprecipitated 
with an anti-DNA-PKCS antibody and analyzed for co-precipitated specific p53 isoforms. (Right) Extracts from [p53-/-] HCT116 cells were 
used to confirm antibody specificity.
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Autophosphorylated DNA-PKCS and p53 form a 
protein complex under pro-apoptotic conditions
Having noted distinct p53 post-translational 
modifications  (phosphorylation/acetylation)  following 
DNA damage that triggered cell cycle arrest or cell 
death (due to continued cycling of DNA damaged cells) 
correlated with disparate p21 promoter recruitment and 
expression, we questioned which upstream activators 
of p53 mediated this response. We examined the three 
major  PI3KK’s ATM, ATR  and  DNA-PKCS since they 
dictate specific p53 responses linked primarily to either 
the induction of cell cycle arrest (ATM/ATR) or apoptosis 
(DNA-PKCS). We found that all three PI3KKs are activated 
(phosphoryation at ser1981 for ATM, ser428 for ATR, and 
thr2609 for DNA-PKCS) under any of the four DNA damage 
conditions (Fig. 3A and S4A). As expected, all ATM and 
ATR phosphorylations were inhibited by the ATM/ATR-
specific inhibitor, CGK-733 [47], but not by the DNA-
PK-specific inhibitor, NU-7026 [48]. However, the use of 
these inhibitors on DNA-PKCS thr2609 phosphorylation 
was revealing. It clearly showed that depending on the 
DNA damage treatment used, this phosphorylation event 
was dictated by different PI3KKs. The DNA-PK inhibitor 
NU-7026 effectively blocked thr2609 phosphorylation 
under pro-death (chromium and gemcitabine) conditions, 
but not under pro-cell cycle arrest (doxorubicin and 
IR) conditions. Conversely, the ATM/ATR inhibitor 
CGK-733 did not block thr2609 phosphorylation under 
damage conditions that lead to cell death (chromium or 
gemcitabine) but its inhibitory effect, albeit partial, under 
pro-arrest conditions (doxorubicin or IR) was evident. 
Our results show that the DNA-PKCS phosphorylated 
(likely via autophosphorylation) under DNA damage 
conditions that lead to cell death is intrinsically different 
from the DNA-PKCS activated (via ATM/ATR [49]) under 
cell cycle arrest conditions. This raises the hypothesis that 
DNA-PKCS activated under certain damage conditions is 
destined to induce cell death by the suppression of cell 
Figure 4: DNA-PKCS forms a complex with p53 on the p21 promoters under pro-apoptotic conditions. (A) ChIP was 
carried out with [p53+/+] HCT116 cells following mock or 6 h post DNA damage with the indicated modalities using the anti-DNA-PKCS 
antibody. PCR was performed for both the distal (-2.2 kb) p21 and proximal (-1.3 kb) p21 promoter regions. Quantification of the bands 
following each DNA damage modality was determined for triplicate studies and represented for each promoter region. (B) ChIP assays were 
conducted as in (A) using an anti-P-thr2609-DNA-PKCS antibody. (C) Top left: ChIP assay for p53 from [p53+/+] HCT116 cells 6 h post 
Cr(VI), Gem, or γ-IR exposure. Top right: ChIP assay for p53 from [p53+/+] HCT116 cells following DNA-PKCS immunodepletion. Bottom 
left: ChIP assay for DNA-PKCS 6 h post DNA damage. Bottom right: ChIP assay for DNA-PKCS following p53 immunodepletion. PCR was 
performed for the distal (-2.2 kb) and the proximal (-1.3 kb) p21 promoter regions. The error bars in all panels represent standard deviation 
obtained from three independent experiments.
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cycle arrest, whereas DNA-PKCS activated under pro-
arrest conditions is poised to perform its DNA repair duty 
following cell cycle arrest.
The specific activation of ATM/ATR and DNA-PK 
under pro-death and pro-arrest conditions following each 
DNA damage regime was also reflected by their specific 
action on p53. Fig. 3B and S4B show that the ATM/ATR 
inhibitor effectively blocked p53 accumulation under pro-
arrest conditions, but not under conditions that actuated 
cell death. Conversely, the DNA-PK inhibitor blocked p53 
Figure 5: p53 recruitment to the p21 promoter precedes DNA-PKCS binding. (A) ChIP assay for p53 or DNA-PKCS from 
[p53+/+] HCT116 cells following Gem exposure for the time points indicated. + indicates 6 h pre-incubation with the ATM/ATR inhibitor 
CGK-733 (20 µM) or the DNA-PK inhibitor NU-7026 (10 µM). PCR was performed for the distal (-2.2 kb) p21 promoter region. (B) ChIP 
assays for p53 or DNA-PKCS were conducted as described in (A) and PCR was performed for the proximal (-1.3 kb) p21 promoter region. 
(C) The quantification of the PCR bands shown in (A) and (B) and two repeated ChIP studies was carried out and normalized to each input 
lane. (D) ChIP assay for p53 or DNA-PKCS from [p53+/+] HCT116 cells following Cr(VI) exposure for the time points indicated. + indicates 
6 h pre-incubation with the ATM/ATR inhibitor CGK-733 (20 µM) or the DNA-PK inhibitor NU-7026 (10 µM). PCR was performed for the 
distal (-2.2 kb) p21 promoter region. (E) ChIP assay for p53 or DNA-PKCS was conducted as described in (D) and PCR was performed for 
the proximal (-1.3 kb) p21 promoter region. (F) The quantification of PCR bands shown in (D) and (E) and two repeated ChIP studies was 
conducted and the values normalized to input samples as described in (C). The boxed areas highlight the effect of the ATM/ATR inhibitor 
on recruitment of early, but not late p53 to the p21 promoter. Error bars for the graphs shown in (C) and (F) represent the standard deviation 
obtained from three independent experiments.
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accumulation under pro-death DNA damage conditions 
(in the absence of cell cycle arrest) but not under pro-
arrest conditions. Thus, p53 accumulation under pro-
death or pro-arrest conditions is dependent on DNA-PKCS 
or ATM/ATR, respectively. This is again consistent with 
the observation that p53 is modified differently under the 
two cell phenotypes.
To further support this observation, we have 
previously shown that murine cell lines expressing 
adenovirus E1A (thus are unable to induce cell cycle 
arrest) undergo cell death post irradiation and that 
DNA-PKCS and p53 form a protein-protein complex 
[34]. To determine if this complex formation occurs in 
human lines and correlates strictly with cell death, co-
immunoprecipitation was carried out on lysates from cells 
damaged under the four DNA damage conditions. We 
found that both gemcitabine and chromium induced the 
formation of a DNA-PKCS/p53 protein complex that was 
not detected following doxorubicin treatment or IR (Fig. 
3C and S4C). These observations, together with the results 
shown in Fig. 3B, raise the hypothesis that p53/DNA-PKCS 
only form a protein/protein complex following DNA-
PKCS autophosphorylation and that when DNA-PKCS is 
phosphorylated by ATM/ATR this protein complex does 
not form. In addition, the p53 bound to DNA-PKCS was 
found to be phosphorylated on ser15, ser37, and ser46, and 
acetylated at lys120, in agreement with our ChIP studies 
(Fig. 3D). It is noteworthy that all of these modifications 
have been strongly linked with enhancing p53-dependent 
apoptosis [24]. Furthermore and consistent with our ChIP 
data, we were unable to detect phospho-ser315 or acetyl-
lys382 p53 in the DNA-PK/p53 complex.
DNA-PKCS/p53 interaction occurs on the p21 
promoter
The observation that p21 promoter-bound p53 and 
p53 bound in a complex with DNA-PKCS are similarly 
modified  led  us  to  hypothesize  that  DNA-PKCS could 
be recruited to the p21 promoters under pro-death DNA 
damage conditions. This was indeed found to be the 
case. We noted the rapid binding of DNA-PKCS to both 
distal and proximal p21 promoters under pro-death (DNA 
damage conditions chromium or gemcitabine) but not pro-
arrest conditions (doxorubicin or IR) in a range of model 
cancer cell lines (Fig. 4A, S5A and S5B). This recruitment 
was  p53-dependent  as  we  could  not  detect  significant 
DNA-PKCS binding to the p21 promoters in similarly 
treated p53-/- HCT116 cells, and no DNA-PKCS binding 
was observed on the GAPDH promoter that was used 
throughout as our negative control. It is noteworthy that 
DNA-PKCS recruitment to the PUMA and Bax promoters 
was negligible relative to the p21 promoters (Fig. 4A), 
and could only be detected at late time points (24 h after 
chromium exposure or 48 h post gemcitabine treatment) 
once the cellular phenotype was markedly apoptotic. As 
expected, the p21 promoters-bound DNA-PKCS was found 
to be phosphorylated at thr2609 (Fig. 4B, S5A and S5B).
To demonstrate that DNA-PKCS recruited to the 
p21 promoters represented the same population that was 
associated with p53, we carried out immune-depletion 
experiments followed by ChIP analysis. Under conditions 
where  p21 transcription was repressed following 
chromium or gemcitabine treatment, immune-depletion of 
nuclear lysates with an anti-DNA-PKCS antibody led to the 
drastic reduction of p53 bound to the p21 promoters (Fig. 
4C). This was not observed with nuclear lysates from IR-
treated cells. Conversely, reciprocal immune-depletion 
with an anti-p53 antibody effectively removed DNA-
PKCS bound to the p21 promoters following chromium 
or gemcitabine treatment while no DNA-PKCS could 
be detected on these promoters following IR treatment. 
Taken together, these studies clearly demonstrate that 
p53 and DNA-PKCS form a protein complex and that this 
complex is localized to the p21 promoter.
We next compared the temporal kinetics of p53 and 
DNA-PKCS recruitment to the p21 promoters. As revealed 
by ChIP analysis, the recruitment of p53 on the proximal 
and distal p21 promoter was detected as early as 30 min 
post DNA damage (gemcitabine or chromium) on the 
distal p21 promoter and 3 h on the proximal promoter 
(Fig. 5A, 5B, 5D and 5E). A similar recruitment profile 
was also observed in the Panc-1 cell line (Fig. S6A, S6B, 
S6C and S6D). In contrast, the temporal recruitment of 
DNA-PKCS was significantly slower than p53, with DNA-
PKCS binding first detected on the distal p21 promoter 
around 3 h and on the proximal promoter approximately 
6 h post damage. This shows that p53 recruitment to both 
p21 promoters precedes that of DNA-PKCS, suggesting 
that the early recruitment of p53 to the p21 promoters is 
likely independent of DNA-PK.
To test the possibility that the early p53 recruitment 
to the p21 promoters could be mediated by ATM/ATR, 
ChIP analyses were carried out using the ATM/ATR 
and DNA-PK inhibitors. We found that the inhibition of 
ATM/ATR by CGK-733 delayed the early, but not the late 
recruitment of p53 to both the distal and proximal p21 
promoters under pro-death conditions (Fig. 5C and 5F, 
indicated on each graph in the boxed area). The temporal 
recruitment of p53 is now more in line with that of DNA-
PKCS which was unaffected by the inhibition of ATM/
ATR. This result indicates that the early recruitment of 
p53 to the p21 promoters is independent of DNA-PKCS 
and mediated by ATM/ATR. Importantly, at later time 
points in the presence of sustained DNA damage there 
was the recruitment of DNA-PKCS to the p21 promoter-
bound p53. The binding of both p53 and DNA-PKCS to 
the p21 promoters was effectively blocked by the DNA-
PK  inhibitor  NU-7026,  consistent  with  significantly 
attenuated p53 protein accumulation (Fig. 3B). A likely 
explanation is that the p53 that initially binds to the p21 Oncotarget 2011; 2:  1094 - 1108 1102 www.impactjournals.com/oncotarget
Figure 6: Inhibition of DNA-PKCS restores p21 expression under pro-apoptotic conditions. (A) Trizol RNA extraction 
was carried out from [p53+/+] HCT116, A549 and Panc-1 cells 12 h post damage; cDNA was generated and the expression level for p21 
was measured. The mRNA expression levels were normalized to GAPDH mRNA, and are represented as fold increase or decrease over 
untreated cells. The DNA-PK inhibitor (NU-7026 [10 µM]) or the ATM/ATR inhibitor (CGK-733 [20 µM]) was pre-incubated for 6 h prior 
to DNA damage. (B) Immunoblot for p21, PUMA or Bax in [p53+/+] HCT116 cells 12 h post DNA damage. + indicates 6 h pre-incubation 
with the DNA-PK inhibitor NU-7026 (10 µM) or the ATM/ATR inhibitor CGK-733 (20 µM). For each gel β-actin indicates loading control. 
(C) Flow cytometric analysis of [p53+/+] HCT116 cells treated as described in (A). The percentage subG1 populations indicated in each 
FACS profile represent the average percentage from three independent experiments (10,000 total events counted per sample). (D) EC50 
values were calculated using MTS assay for the [p53+/+] HCT116, A549 and Panc-1 cell lines 48 h post Cr(VI), Gem or Doxo treatment. 
The error bars for (D) represent the standard deviation obtained from three independent experiments.
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promoter at earlier time points becomes further modified 
at later times by DNA-PKCS following its recruitment to 
the promoter.
DNA-PKCS inhibition restores p21 expression and 
increases cell survival
We then questioned what the effect of DNA-PK 
inhibition would be on downstream p53-regulated genes 
under the various DNA damage conditions. Strikingly, 
repression of p21 transcription following chromium or 
gemcitabine treatment was effectively reversed upon 
inhibition of DNA-PK, with the transcription of p21 
restored to levels comparable to those prior to damage 
(Fig. 6A) whereas inhibition of ATM/ATR had no effect 
suggesting that under these conditions DNA-PKCS represses 
p21 transcription. In contrast, under pro-arrest conditions 
(doxorubicin or IR), p21 transcription was ablated when 
ATM/ATR was inhibited, whereas the inhibition of DNA-
PK had no effect. This is consistent with the loss of p53 
protein accumulation following the inhibition of ATM/
ATR under pro-arrest conditions (Fig. 3B). In contrast 
to p21, chromium and gemcitabine exposure elicited an 
increase in both PUMA and Bax transcription (Fig. S7A) 
that was blocked by the DNA-PK inhibitor but not the 
ATM/ATR inhibitor. Enhanced expression of PUMA and 
Bax was also evident under pro-arrest conditions however 
this enhancement was ATM/ATR-dependent as it was 
blocked by CGK-733. As expected, in the absence of p53, 
there was little to no p53-regulated gene expression and 
that following treatment with each DNA damage modality 
there was limited transcription of these genes which was 
not  significantly  affected  by ATM, ATR  or  DNA-PKCS 
inhibition (Fig. S8B). It is noteworthy that these responses 
were conserved in a range of cancer cell lines (Fig. S7C 
and S7D).
The protein expression levels under each DNA 
damage condition was also examined and was found 
to be consistent with our gene expression results (Fig. 
6B). Following chromium or gemcitabine exposure 
there was the loss of the p21 protein. In contrast, there 
was significant accumulation of both PUMA and Bax. 
Inhibition of DNA-PKCS restored p21 protein levels while 
reducing the levels of PUMA and Bax, consistent with 
our transcription studies. Furthermore, as predicted from 
our gene expression experiments, inhibition of ATM/ATR 
was unable to rescue the loss of the p21 protein and had 
no effect on the elevated PUMA and Bax protein levels. 
In contrast to chromium and gemcitabine treatment, both 
doxorubicin and IR exposure significantly increased the 
levels of all three proteins (p21, PUMA and Bax) in an 
ATM/ATR-dependent manner. Similar observations were 
made using the Panc-1 cell line (Fig. S8). Taken together, 
these observations are congruent with the notion that cell 
fate is dependent more on the regulation of expression of 
pro-survival genes (such as p21) than on the regulation of 
expression of pro-death genes (such as PUMA and Bax) 
and that DNA-PK and ATM/ATR play antagonistic roles 
in dictating these events.
To test this hypothesis we exposed cells to each 
damage agent in the presence of either the ATM/ATR 
inhibitor or the DNA-PK inhibitor. At 48 hours following 
Cr(VI) or gemcitabine exposure we note the significant 
accumulation of a sub-G1 population. In contrast and 
as predicted, doxorubicin or IR treatment induced cell 
cycle arrest (Fig. 6C). The inhibition of ATM/ATR did 
not  significantly  alter  the  sub-G1 population following 
Cr(VI) or gemcitabine treatment however as expected it 
did increase the sub-G1 population after doxorubicin or 
IR treatment [50, 51]. DNA-PK inhibition significantly 
reduced the sub-G1 population after Cr(VI) or gemcitabine 
exposure  but  had  no  discernable  effect  48  hours  post-
doxorubicin or IR treatment. To complement our FACS 
approach we determined cell viability (EC50) for each 
chemical when ATM/ATR or DNA-PK was inhibited 
(Fig. 6D). In support of our data shown in Figure 6C, 
the  inhibition  of  DNA-PK  significantly  increased  cell 
viability after Cr(VI) or gemcitabine treatment but had no 
effect on cell viability following doxorubicin treatment. 
(We were unable to determine an EC50 value following 
IR treatment at 48 hours post damage). The inhibition of 
ATM/ATR did not significantly alter (although did lower) 
the EC50 for Cr(VI) or gemcitabine, however, it did cause a 
noticeable decrease (P=0.0259) in cell viability following 
doxorubicin treatment. In this regard it is interesting to 
note that a recent study showed that upon camptothecin 
treatment, ATM activation leads to cell cycle arrest, 
however when absent or inhibited, there is hyper DNA-
PKCS activation causing cell death [38]. We also addressed 
a previous report that demonstrated over expression of 
Myc can suppress p21 transcription by forming a protein 
complex with Miz1 on the proximal p21 promoter [52]. 
Our results indicate that the endogenous suppression of p21 
transcription following either gemcitabine or chromium 
exposure is DNA-PKCS dependent and independent of 
Myc/Miz-1 (Fig. S9).
DISCUSSION
The present study reveals a mechanism whereby a 
key DNA damage sensor upstream of p53 is linked to a 
major effector protein downstream of p53, leading to cell 
death (Fig. 7). We demonstrate that under DNA damage 
conditions which induce p53-dependent cell death there 
is recruitment of DNA-PKCS to the p21 promoter. This 
promoter recruitment occurs by DNA-PKCS binding 
to p53 on the p53 responsive elements within the p21 
promoter after DNA-PKCS autophosphorylation. Upon 
DNA-PKCS promoter binding, there is the rapid loss of 
p21 transcription and the p21 protein. As a result of this 
ablated mRNA expression and subsequent protein loss, Oncotarget 2011; 2:  1094 - 1108 1104 www.impactjournals.com/oncotarget
the cell is unable to induce cell cycle arrest and continues 
to cycle in the presence of sustained DNA damage. In 
striking contrast, under the same cellular conditions there 
is no DNA-PKCS recruitment on pro-apoptotic promoters 
(PUMA or Bax) and consequently there is the elevated, 
continuous transcription of PUMA and Bax, producing a 
cellular environment that rapidly drives the cell towards 
apoptosis.
A most important aspect of the present model is 
that it reconciles a number of key observations made 
through the years pertaining to the complex interplay 
between ATM, p53, p21, and importantly, DNA-PK, and 
amalgamates them into a single unifying mechanistic 
concept pertaining to the transcription regulation of p21. 
Under conditions that favor cell cycle arrest, the ATM/
ATR signaling pathway is activated, triggering a p53 
phosphorylation/acetylation cascade involving key p53 
“arrest-specific” residues (e.g. phosphorylation at ser15 
and  ser315,  and  acetylation  at  lys382).  Following  p21 
promoter recruitment this “modified” p53 activates p21 
transcription, and cell cycle arrest ensues. Under pro-
death conditions, the recruitment of DNA-PKCS to the p21 
promoter apparently initiates a separate and different p53 
phosphorylation/acetylation cascade (e.g. phosphorylation 
at ser15, ser37, ser46 and acetylation at lys120), which 
results in the abrogation of p21 transcription. While 
precisely how the cell senses pro-arrest versus pro-death 
stress signals is unclear at present, a glimpse of the 
mechanisms involved in the transition from the pro-arrest 
to pro-death state could be gleaned from the time course 
experiment presented in Figure 5. During earlier times 
upon exposure to Cr(VI) or Gemcitabine, the recruitment 
of p53 to the p21 promoter precedes that of DNA-PKCS, 
and that this recruitment is ATM/ATR-dependent. This 
“early  bound”  p53  likely  functions  as  an  activator  of 
p21 transcription, priming the cell for cell cycle arrest. 
Concomitantly, at these earlier times, DNA-PKCS is 
phosphorylated, and this phosphorylation event is also 
ATM/ATR-dependent. It is tempting to speculate that the 
damaged cell is utilizing ATM/ATR to activate and couple 
p53’s pro-arrest function with DNA-PK’s DNA repair 
function. Indeed, recent evidence supports such a cross-
talk between ATM/ATR and DNA-PK in situations where 
the repair of the damaged DNA is still a viable option [49, 
53]. Under pro-death conditions, DNA-PK undergoes 
autophosphorylation, binds to and modifies p53 on the 
p21 promoter, incapacitating p53’s transcription activation 
function, and priming the cell to induce apoptosis by the 
ablation of p21 expression. Although additional details 
will need to be worked out (e.g. the specific and sequential 
involvement of kinases and phosphatases, acetylases and 
deacetylases, and other p53 modifying enzymes etc.), the 
proposed model represents a general framework whereby 
ATM/ATR and DNA-PK are portrayed as key opposing 
players that dictate cell fate through the manipulation of a 
common switch, that of p53-mediated p21 transcription.
Our results lend credence to the intriguing notion 
that DNA-PK has dual roles, the first being its classically 
defined DNA repair role of mediating non-homologous 
end joining (NHEJ) and the second being its emerging role 
Figure 7: Model for DNA-PKCS-mediated repression of p21 transcription and induced cell death. Under pro-arrest conditions 
(e.g. IR or Doxo), ATM/ATR is activated and modifies p53 promoting p21 transcription and inducing cell cycle arrest. Concurrently, ATM/
ATR phosphorylates DNA-PKCS, priming the latter for its DNA repair function. Under pro-death damage conditions (e.g. Cr(VI) or Gem), 
DNA-PKCS undergoes autophosphorylation independently of ATM/ATR. DNA-PKCS binds to p53 on the p21 promoter, resulting in the 
abrogation of p21 transcription. By preventing the accumulation of p21, DNA-PKCS suppresses cell cycle arrest and p21-mediated survival, 
directing the cell towards cell death.
Hill Figure 7.
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of driving apoptosis. It would seem logical to view these 
two roles as being mutually exclusive, which would in 
turn suggest the existence of a switch mechanism capable 
of exerting opposing biochemical and functional control 
of DNA-PK. While DNA-PK’s DNA repair function 
necessitates its binding to broken DNA ends, the nature 
of putative DNA-PK binding to promoter elements is less 
clear. In this regard, it is noteworthy that signal-dependent 
activation of gene transcription has been shown to involve 
topoisomerase IIβ-dependent transient double strand DNA 
breaks with subsequent activation of poly(ADP-ribose) 
polymerase-1 (PARP-1) enzymatic function [54, 55], 
which could involve the recruitment of DNA-PK to the 
promoter site. While it remains to be seen how common 
DNA-PK-mediated transcription regulation through 
promoter binding occurs, the present study shows that the 
potential role of DNA-PK in apoptosis and cancer control 
cannot be understated and warrants further investigation.
METHODS
Cell lines and reagents
[p53+/+] HCT116 and [p53-/-] HCT116 human colon 
carcinoma cells were maintained in McCoy’s 5A medium. 
A549 and Panc-1 human lung and pancreatic carcinoma cell 
lines were maintained in DMEM. All were supplemented 
with 10% FBS and antibiotics. Antibodies shown in 
supplemntal table 1 were used for our immunoblots and 
visualization of signal was achieved using an Odyssey® 
Infrared Imaging System (Licor Bioscience, US). 
Doxorubicin (Sigma, US), gemcitabine hydrochloride 
(Eli Lilly #VL7502), chromium(VI) (potassium chromate 
(#03377 Sigma, US) were used at a concentration of 0.5 
µM, 10 µM and 30 µM respectively. γ-Radiation (10 Gy) 
was delivered by a 137Cs gamma radiator (MDS Nordion) 
at 2.5 Gy min-1. Cells were pre-incubated with either the 
DNA-PK inhibitor NU-7026 (10 µM) or the ATM/ATR 
inhibitor CGK-733 (20 µM) (Tocris Bioscience, US) for 6 
h prior to DNA damage.
Cell viability (MTS) assay
Cells were seeded in 96-well plates at 1 x 104 cells/well 
and 24 hr later treated with various DNA damaging agents 
Doxorubicin (Sigma, US), gemcitabine hydrochloride 
(Eli Lilly #VL7502), chromium(VI) (potassium chromate 
(#03377 Sigma, US) or γ-Radiation at the concentrations 
described. At the time points indicated post-treatment, cell 
survival was determined by CellTiter 96© Aqueous non-
radioactive proliferation assay (MTS assay; Promega, 
CA, USA) following the manufactures guidelines.
Nuclear and cytoplasmic fractionation
Cells were washed once with ice cold PBS and then 
1 ml of hypotonic lysis buffer (20 HEPES, 10 mM NaCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 20% glycerol, 0.1% triton 
X-100, 100 mM DTT, 1 mM AEBSF, 1 mM PIC) was 
added to each pellet. Nuclear fractions were harvested in 
hypertonic lysis buffer (20 mM HEPES, 500 mM NaCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 20% glycerol, 0.1% 
Triton X-100, 10 mM DTT, 1 mM AEBSF, 1 mM PIC).
Co-immunoprecipitation
Co-immunoprecipitations (Co-IP) were performed 
as described in [34]). Cells were lysed in cold lysis buffer 
(50 mM Tris-Cl at pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1% NP-40, 0.25% sodium deoxycholate, protease inhibitor 
mixture). Cell extracts (500 μg) were incubated with the 
first antibodies (supplemental table S1) or control normal 
IgG on a rotator overnight at 4°C, followed by addition of 
protein G magnetic beads (Invitrogen, US) for 2 h at 4°C. 
Beads were then washed four times using the lysis buffer. 
The  immune  complexes  were  subjected  to  SDS-PAGE 
followed by immunoblotting with the secondary antibody.
Western blot analysis
For the preparation of whole cell lysate, cells were 
harvested and lysed using RIPA buffer (50 mM Tris-HCl 
pH 7.4, 1% NP-40, 0.5% Na-deoxychlorate, 150 mM 
NaCl, 1 mM EDTA, 2 mM NaF, 2 mM NaVO4 and 1x 
protease inhibitor cocktail (PIC) (Sigma, US)). For SDS–
PAGE, protein samples were boiled for 5–10 min in protein 
sample buffer (50 mM Tris pH 6.8, 1% SDS, 10% glycerol, 
0.01%  Bromophenol  Blue,  β  mercaptoethanol  [50  µL 
per 950 µL sample buffer]). Following electrophoresis, 
proteins were transferred onto nitrocellulose membrane 
(BioRad, US). The membrane was blocked for for 1 hour at 
room temperature or overnight at 4°C using 1X Odyssey® 
blocking buffer (Li-Cor, US). Primary antibodies were 
added to the membrane (supplemental table S1) overnight 
at 4°C or for 2 hours at room temperature. Secondary 
antibody was added (Licor, US) at typically 1:10,000 
dilution for 1 hour at room temperature. Visualisation of 
signal was achieved using an Odyssey Infrared Imaging 
System (Li-Cor, US).
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) assays were 
performed essentially the same as described by Kaeser 
et al and Mattia et al [56, 57]. Briefly, cells were fixed 
with 1% formaldehyde, and then whole-cell lysates were 
prepared. Protein lysate was subjected to ChIP with the Oncotarget 2011; 2:  1094 - 1108 1106 www.impactjournals.com/oncotarget
indicated antibodies (Supplemental table S1), followed by 
DNA purification. ChIP-enriched DNA was analyzed by 
PCR with the indicated primer sets (Supplemental Table 
S3). Visualization of bands was achieved using a Typhoon 
Phospho-imager (Amersham, UK) and quantified using 
the Image-Quant software (Amersham, UK).
Quantitative Real time PCR (qRT-PCR)
Total RNA was extracted by using Trizol (Invitrogen). 
Real Time PCR was performed on a Stratagene MX3000P 
PCR machine using the Stratagene Sybr® green master 
mix (Stratagene, Canada). The primer sequences for 
measuring p21, Bax, PUMA, MDM2 and GAPDH were 
purchased from Invitrogen and are shown in supplemental 
table S2. Data analysis was carried out using the 2-∆∆CT 
method described by [58].
Flow cytometric cell cycle analysis
Cells  were  grown  to  60%  confluence.  BrdU  was 
added to the medium 2 hours prior to DNA damage. Cells 
were mock treated/exposed to each DNA damage agent 
for 4 hours (in the presence of the DNA damage agent 
or following IR treatment). This corresponded to the 6 
hour damage sample. Additional time points investigated 
were 0 hr (cells incubated in BrdU containing medium 
for 4 hours prior to sample collection), 2 hr, 12 hr, 24 
hr and 48 hr. BrdU labeling was carried out utilizing an 
anti-BrdU-FITC antibody (Becton Dickinson) following 
the manufacturer’s instructions. Samples were run on a 
Fluorescence Activated Cell Scanner (FACS) and the 
percentage with incorporated BrdU, the sub-G1 (non-
viable apoptotic) population and the BrdU negative non-
subG1 (viable) populations determined. 20,000 total events 
were scored per study BrdU was added to the medium 2 
h prior to DNA damage. BrdU labeling utilizing an anti-
BrdU-FITC antibody (#555627 BD Biosciences, US) was 
conducted and propidium iodide (2.5 mg mL-1) was added 
to the fixed, stained cells prior to analysis. 20,000 total 
events were scored per study from triplicate studies. Data 
was analyzed using FACS-express 3 (De Novo software, 
US).
Statistical analysis
Statistical  significance  was  assessed  by  one-way 
ANOVA  or  the  two-tailed  Students  t-test. Statistical 
significance was defined as P < 0.05. Results are expressed 
as the mean ±SD.
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